Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Shareholder Update

<< Previous

Bullboard Posts

Next >>

Post by Forestviewon Aug 12, 2021 3:24pm

231 Views

Post# 33695394

Shareholder Update

Any idea if we can expect a Shareholder update soon from Dan after this? I suspect they'll wait out the 14 day window...but there's a lot of uncertainty, as the past two days on here highlight, and no one really knows anything until we hear from Dan. The AGM is next week...what do you think they'll say then?

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading